Tatva Chintan Pharma Chem Ratios

Tatva Chintan Pharma Chem Ltd Ratios

The Tatva Chintan Pharma Chem Ltd Ratios page provides a complete fundamental analysis of Tatva Chintan Pharma Chem Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Tatva Chintan Pharma Chem Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Tatva Chintan Pharma Chem Ltd (NSE: TATVA, BSE: 543321) is currently trading at ₹1052.40, with a market capitalization of ₹24.58B. As a major player in the Process industries sector and Chemicals: specialty industry, Tatva Chintan Pharma Chem Ltd remains a key stock for fundamental analysis using Tatva Chintan Pharma Chem Ltd Ratios.

Tatva Chintan Pharma Chem Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Tatva Chintan Pharma Chem Ltd P/E ratio currently stands at 278, making it one of the most tracked metrics in Tatva Chintan Pharma Chem Ltd Ratios.

Historically, the Tatva Chintan Pharma Chem Ltd P/E ratio has shown strong fluctuations:

• 2024: 278
• 2023: 81.41
• 2022: 81.23
• 2021: 51.75
• 2020: 0

The rising Tatva Chintan Pharma Chem Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Tatva Chintan Pharma Chem Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.15.

Historical P/B trend:

• 2024: 2.15
• 2023: 3.43
• 2022: 7.18
• 2021: 10.81

Tatva Chintan Pharma Chem Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Tatva Chintan Pharma Chem Ltd P/S ratio currently stands at 4.16, an important part of Tatva Chintan Pharma Chem Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 4.16
• 2023: 6.29
• 2022: 8.73
• 2021: 11.46

A stable or declining Tatva Chintan Pharma Chem Ltd P/S ratio indicates cautious market sentiment.

Tatva Chintan Pharma Chem Ltd Price to Cash Flow Ratio (P/CF)

The Tatva Chintan Pharma Chem Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 66.54.

Historical Tatva Chintan Pharma Chem Ltd Price to Cash Flow Ratio:

• 2024: 66.54
• 2023: 26.07
• 2022: 149.56
• 2021: 248.85
• 2020: 0

The rising Tatva Chintan Pharma Chem Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Tatva Chintan Pharma Chem Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Tatva Chintan Pharma Chem Ltd EV currently stands at ₹16.1B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 16.1B
• 2023: 24.37B
• 2022: 38.2B
• 2021: 49.04B

Tatva Chintan Pharma Chem Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Tatva Chintan Pharma Chem Ltd EV/EBITDA ratio is currently 43.86, a key metric in Tatva Chintan Pharma Chem Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 43.86
• 2023: 35.93
• 2022: 56.60
• 2021: 45.09

Higher Tatva Chintan Pharma Chem Ltd EV/EBITDA suggests premium valuation.

Tatva Chintan Pharma Chem Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Tatva Chintan Pharma Chem Ltd D/E ratio is currently 0.05, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.05
• 2023: 0.02
• 2022: 0.33
• 2021: 0.25

Tatva Chintan Pharma Chem Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Tatva Chintan Pharma Chem Ltd ROE currently stands at 0.77%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 0.77
• 2023: 4.85
• 2022: 9.21
• 2021: 30.01

Declining ROE indicates pressure on profitability.

Tatva Chintan Pharma Chem Ltd Ratios Analysis Summary

The Tatva Chintan Pharma Chem Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Tatva Chintan Pharma Chem Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Tatva Chintan Pharma Chem Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.